Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a research report on Monday, July 29th.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $0.96 on Monday. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $2.15. The firm has a market capitalization of $52.47 million, a price-to-earnings ratio of -2.67 and a beta of 0.56. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm’s fifty day simple moving average is $1.12 and its 200 day simple moving average is $1.01.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. CM Management LLC grew its stake in Cytosorbents by 98.8% during the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after purchasing an additional 410,000 shares in the last quarter. Avenir Corp grew its position in shares of Cytosorbents by 4.0% during the first quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock worth $3,014,000 after buying an additional 121,294 shares in the last quarter. Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the last quarter. Atomi Financial Group Inc. acquired a new stake in Cytosorbents in the third quarter valued at $51,000. Finally, Geode Capital Management LLC boosted its stake in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.